Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
Royalties increased by 7% to $111.7 million in the second quarter of 2022, compared to the same quarter in 2021
Completed acquisition of the remaining approximately 40% of Entasis Therapeutics at a price of $2.20 per share for a consideration of $42 million in July 2022
Entered into definitive merger agreement to acquire all outstanding shares of La Jolla Pharmaceutical Company for $6.23 per share in cash at an implied enterprise value of $149 million in July 2022
Sold 15% economic stake in Theravance Respiratory Company ("TRC") to Royalty Pharma for approximately $282 million and a potential $50 million milestone payment plus full ownership of existing equity investments TRC previou
